Effect of intratympanic dexamethasone administration on cisplatin-induced ototoxicity in adult guinea pigs

Auris Nasus Larynx

Volumn 40, Issue 1, 2013, Pages 51-60

  Shafik, Amr G ^a   Elkabarity, Rasha H ^a   Thabet, Mirahan T ^a   Soliman, Nevine B ^a   Kalleny, Nagwa K ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Cisplatin; Dexamethasone; Guinea pigs; Ototoxicity

Indexed keywords

CISPLATIN; DEXAMETHASONE; SODIUM CHLORIDE;

ADULT ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUDIOLOGY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EAR PROTECTION; EARDRUM; GUINEA PIG; HISTOLOGY; MALE; NONHUMAN; OTOTOXICITY; STEROID THERAPY;

ACOUSTIC STIMULATION; ANIMALS; ANTINEOPLASTIC AGENTS; AUDITORY THRESHOLD; CISPLATIN; COCHLEA; DEXAMETHASONE; DISEASE MODELS, ANIMAL; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; GLUCOCORTICOIDS; GUINEA PIGS; HEARING LOSS; INJECTIONS; MALE; MICROSCOPY; MICROSCOPY, ELECTRON, SCANNING; TYMPANIC MEMBRANE;

EID: 84873080565     PISSN: 03858146     EISSN: 18791476     Source Type: Journal    
DOI: 10.1016/j.anl.2012.05.010     Document Type: Article

References (50)

1. Rybak L., Whitworth C. Ototoxicity: therapeutic opportunities. Drug Discov Today 2005, 10:1313-1321.
2. Bokemeyer C., Berger C.C., Hartmann J.T., Kollmannsberger C., Schmoll H.J., Kuczyk M.A., et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998, 77:1355-1362.
3. Rybak L., Mukherjea D., Jajoo S., Ramkumar V. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med 2009, 219:177-186.
4. Rybak L., Whitworth C., Mukherjea D., Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2007, 226:157-167.
5. Bird P.A., Murray D.P., Zhang M., Begg E.J. Intratympanic versus intravenous delivery of dexamethasone and dexamethasone sodium phosphate to cochlear perilymph. Otol Neurotol 2011, 32:933-936.
6. Herr I., Ucur E., Herzer K., Okouoyo S., Ridder R., Krammer P.H., et al. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res 2003, 63:3112-3120.
7. Hargunani C., Kempton J., DeGagne J., Trune D. Intratympanic injection of dexamethasone: time course of inner ear distribution and conversion to its active form. Otol Neurotol 2006, 27:564-569.
8. Kara E., Cetik F., Tarkan O., Sürmelioĝlu O. Modified intratympanic treatment for idiopathic sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol 2010, 267:701-707.
9. Barrs D.M. Intratympanic corticosteroids for Meniere's disease and vertigo. Otolaryngol Clin North Am 2004, 37:955-972.
10. Hill G., Morest D., Parham K. Cisplatin-induced ototoxicity: effect of intratympanic dexamethasone injections. Otol Neurotol 2008, 29:1005-1011.
11. Ekborn A., Laurel G., Ehrsson H., Miller J. Intracochlear administration of thiourea protects against cisplatin-induced outer hair cell loss in the guinea pig. Hear Res 2003, 181:109-115.
12. Dang V., Bao S., Ault A., Murray C., Mills J.M., Chiedi C., et al. Efficacy and safety of five injectable anesthetic regimens for chronic blood collection from the anterior vena cava of guinea pigs. J Am Assoc Lab Anim Sci 2008, 47:56-60.
13. Kalcioglu M.T., Kizilay A., Gulec M., Karatas E., Iraz M., Akyol O., et al. The protective effect of erdosteine against ototoxicity induced by cisplatin in rats. Eur Arch Otorhinolaryngol 2005, 262:856-863.
14. Ramírez-Camacho R., Citores M.J., Trinidad A., Verdaguer J.M., García-Berrocal J.R., Marero A.M., et al. HSP-70 as a nonspecific early marker in cisplatin ototoxicity. Acta Otolaryngol 2007, 127:564-567.
15. Bancroft J.D., Gamble M. Theory and Practice of Histological Techniques 2008, Churchill Livingstone ElSevier, p. 126. 6th ed.
16. Kaltenbach J., Rachel J., Mathog A., Zhang J., Falzarano P., Lewandowski M. Cisplatin-induced hyperactivity in the dorsal cochlear nucleus and its relation to outer hair cell loss: relevance to tinnitus. J Neurophysiol 2002, 88:699-714.
17. Zuur C.L., Simis Y.J., Lansdaal P.E., Hart A.A., Schornagel J.H., Dreschler W.A., et al. Ototoxicity in a randomized phase III trial of intraarterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J Clin Oncol 2007, 25:3759-3765.
18. Blakley B.W., Hochman J., Wellman M., Gool A., Hussain A.E. Differences in ototoxicity across species. J Otolaryngol Head Neck Surg 2008, 37:700-703.
19. Ramirez-Camacho R., Garcia-Berrocal J., Bujan J., Martin-Marero A., Trinidad A. Supporting cells as a target of cisplatin-induced inner ear damage: therapeutic implication. Laryngoscope 2004, 114:533-537.
20. De Freitas M.R., Figueiredo A.A., Brito G.A., Leitao R.F., Carvalho Junior J.V., Gomes Junior R.M., et al. The role of apoptosis in cisplatin-induced ototoxicity in rats. Braz J Otorhinolaryngol 2009, 75:745-752.
21. Salt A.N. Dexamethasone concentration gradients along scala tympani after application to the round window membrane. Otol Neurotol 2008, 29:401-406.
22. Sha S.H., Taylor R., Forge A., Schacht J. Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. Hear Res 2001, 155:1-8.
23. Garcia-Berrocal J.R., Nevado J., Ramirez-Camacho R., Sanz R., Gonzalez-Garcia J.A., Sanchez-Rodriguez C., et al. The anticancer drug cisplatin induces an intrinsic apoptotic pathway inside the inner ear. Br J Pharmacol 2007, 152:1012-1020.
24. Osborne M., Comis S. High resolving scanning electron microscopy of stereocilia in the course of normal, postmortem and drug-treated guinea pigs. Electron Microsc Tech 1990, 15:245-260.
25. Wang J., Ladrech S., Pujol R., Brabet P., Van De Water T.R., Puell J.L. Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss. Cancer Res 2004, 64:9217-9224.
26. Cardinaal R.M., de Groot J.C.M.J., Huizing E.H., Smoorenburg G.F., Veldman J.E. Ultrastructural changes in the adult guinea pig cochlea at different survival times following cessation of 8 day cisplatin administration. Otolaryngology 2004, 124:144-154.
27. Lee J.E., Nagakawa T., Kita T., Kim T.S., Iguchi F., Endo T., et al. Mechanisms of apoptosis induced by cisplatin in marginal cells in mouse stria vascularis. ORL J Otorhinolaryngol Relat Spec 2004, 66:111-118.
28. Daldal A., Odabasi O., Serbetcioglu B. The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs. Otolaryngol Head Neck Surg 2007, 137:747-752.
29. So H., Kim H., Kim Y., Kim E., Pae H.O., Chung H.T., et al. Evidence that cisplatin-induced auditory damage is attenuated by downregulation of proinflammatory cytokines via Nrf2/HO-1. J Assoc Res Otolaryngol 2008, 9:290-306.
30. Van Ruijven M.W.M., de Groot J.C.M.J., Klis S.F.L., Smoorenburg G. Cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res 2005, 205:241-248.
31. More S.S., Akil O., Ianculescu A.G., Geier E.G., Lustig L.R., Giacomini K.M. Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci 2010, 30:9500-9509.
32. Ding D., He J., Allman B.L., Yu D., Jiang H., Seigel G.M., et al. Cisplatin ototoxicity in rat cochlear organotypic cultures. Hear Res 2011, 12. [Epub ahead of print].
33. Caronia D., Patino-Garcia A., Milne R.L., Zalacain-Diez M., Pita G., Alonso M.R., et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 2009, 9:347-353.
34. Rybak L.P., Husain K., Morris C., Whitworth C., Somani S. Effect of protective agents against cisplatin ototoxicity. Am J Otol 2000, 21:513-520.
35. Mukherjea D., Jajoo S., Whitworth C., Bunch J.R., Turner J.G., Rybak L.P., et al. Short interfering RNA against transient receptor potential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat. J Neurosci 2008, 28:13056-13065.
36. Devaux P.F. Protein involvement in transmembrane lipid asymmetry. Annu Rev Biophys Biomol Struct 1992, 21:417-439.
37. Bitbol M., Fellmann P., Zachowski A., Devaux P.F. Ion regulation of phosphatidylserine and phosphatidylethanolamine outside-inside translocation in human erythrocytes. Biochim Biophys Acta 1987, 904:268-282.
38. Zhou Q., Zhao J., Stout J.G., Luhm R.A., Wiedmer T., Sims P.J. Molecular cloning of human plasma membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phospholipids. J Biol Chem 1997, 272:18240-18244.
39. Liang F., Schulte B.A., Qu C., Hu W., Shen Z. Inhibition of the calcium- and voltage-dependent big conductance potassium channel ameliorates cisplatin-induced apoptosis in spiral ligament fibrocytes of the cochlea. Neuroscience 2005, 135:263-271.
40. Salt A.N., Plontke S.K. Principles of local drug delivery to the inner ear. Audiol Neurotol 2009, 14:350-360.
41. Banerjee A., Parnes L.S. The biology of intratympanic drug administration and pharmacodynamics of round window drug absorption. Otolaryngol Clin North Am 2004, 37:1035-1051.
42. Parnes L.S., Sun A.H., Freeman D.J. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 1999, 109:1-17.
43. Liu H.J., Dong M.M., Chi F.L. Structure and function influence of cochlear after dexamethasone intratympanic application. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2005, 40:440-443.
44. Wang X., Fernandez R., Dellamary L., Harrop A., Ye Q., Lichter J., et al. Pharmacokinetics of dexamethasone solution following Intratympanic Injection in guinea pig and sheep. Audiol Neurotol 2010, 16:233-241.
45. Ahn J.H., Yoo M.H., Yoon T.H., Chung J.W. Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?. Laryngoscope 2008, 118:279-282.
46. Pondugula S.R., Raveendran N.N., Ergonul Z., Deng Y., Chen J., Sanneman J.D., et al. Glucocorticoid regulation of genes in the amiloridesensitive sodium transport pathway by semicircular canal duct epithelium of neonatal rat. Physiol Genomics 2006, 24:114-123.
47. Ishiyama G., Lopez I.A., Ishiyama A. Aquaporins and Meniere's disease. Curr Opin Otolaryngol Head Neck Surg 2006, 14:332-336.
48. Hamid M., Trune D. Issues, indications, and controversies regarding intratympanic steroid perfusion. Curr Opin Otolaryngol Head Neck Surg 2008, 16:434-440.
49. Paksoy M., Ayduran E., Sanli{dotless} A., Eken M., Aydi{dotless}n S., Oktay Z.A. The protective effects of intratympanic dexamethasone and vitamin E on cisplatin-induced ototoxicity are demonstrated in rats. Med Oncol 2011, 28:615-621.
50. Meltser I., Canlon B. Protecting the auditory system with glucocorticoids. Hear Res 2011, 281:47-55.